Hallucinogen use, unspecified
ICD-10 F16.9 is a billable code used to indicate a diagnosis of hallucinogen use, unspecified.
Hallucinogen use, unspecified (F16.9) refers to the consumption of hallucinogenic substances without specific identification of the substance or the context of use. Hallucinogens are a class of psychoactive substances that alter perception, mood, and various cognitive processes. Common hallucinogens include LSD, psilocybin (magic mushrooms), and mescaline. Individuals may use these substances recreationally or as part of a therapeutic regimen. The clinical presentation can vary widely, with symptoms ranging from visual and auditory hallucinations to profound alterations in thought processes and emotional states. The use of hallucinogens can lead to substance use disorders characterized by compulsive use despite adverse consequences. Withdrawal symptoms are generally less severe than those associated with other substances, but psychological effects can persist. Treatment often involves psychotherapy, support groups, and in some cases, medication to manage co-occurring mental health disorders. Accurate coding is essential for appropriate treatment planning and insurance reimbursement.
Detailed patient history, including substance use patterns and mental health status.
Patients presenting with acute psychosis or mood disturbances related to hallucinogen use.
Consideration of underlying mental health conditions and the impact of hallucinogen use on treatment.
Comprehensive assessment of substance use, including frequency, quantity, and impact on daily functioning.
Patients seeking help for hallucinogen-related issues, including cravings and withdrawal symptoms.
Focus on harm reduction strategies and integration of behavioral therapies.
Used when assessing a patient for hallucinogen use.
Document the assessment findings and treatment recommendations.
Psychiatry and addiction medicine may require specific assessment tools.
Document the patient's substance use history, any symptoms experienced, and the impact on their daily life. Include details about treatment plans and any co-occurring mental health conditions.
